colorectal cancer: future horizons experts' meeting
TRANSCRIPT
Colorectal Cancer:Colorectal Cancer:
International Experts MeetingInternational Experts Meeting
LondonLondon
Thursday 25th June 2015Thursday 25th June 2015
Future HorizonsFuture Horizons
Symposium and Symposium and
Inaugural Lecture Inaugural Lecture
ProgrammeProgramme
Royal Society of Medicine
1, Wimpole Street
London W1G 0AE
08.00 - 08.45 REGISTRATION 1 WIMPOLE STREET FOYER, ROYAL SOCIETY OF MEDICINE
08.45 - 09.00 Welcome and introduction
Prof Gina Brown Royal Marsden Hospital and Imperial College, London, UK
09.00 - 09.30
Prof Bill Heald Pelican Cancer Foundation, Basingstoke, UK
09.30 - 10.35
Session objectives:
Chairs Prof Soren Laurberg Aarhus University, DK
Dr Erin Kennedy University of Toronto, CA
09.30 Session introduction
Prof Gina Brown Royal Marsden Hospital and Imperial College, London, UK
09.35
Prof Steven Wexner Cleveland Clinic, Florida, US
09.45
Prof Robert Madoff University of Minnesota, US
09.55
Prof Anna Martling Karolinska Institute, Stockholm, SE
10.05
Prof David Sebag-Montefiore University of Leeds, UK
Prof Andrea Rockall Imperial College, London, UK
Dr Hideaki Yano National Center for Global Health and Medicine, Tokyo, JP
Dr Joachim Straßburg Friedrichshain Hospital, Berlin, DE
10.35 - 11.05 MORNING COFFEE CAVENDISH ROOM AND MAX RAYNE FOYER
Anything is Possible: The importance of friendships and collaboration in changing global
surgical practice - the art of friendly persuasion
Synoptic reporting, economic and resource challenges
Training measures can these be implemented globally and how?
Reaching a consensus for prioritising standards
SESSION ONE: SHOULD WE BE SETTING THE STANDARDS FOR COLORECTAL CANCER CARE
GLOBALLY?
The evolution and development of the MDT approach USA, European and UK experiences - what
can we do better?
Colon cancer - ten years behind the rectum?
The surgeon as a prognostic factor in colon and rectal cancer?
EXPERT ROUND TABLE DISCUSSION OF SESSION OBJECTIVES
Colorectal Cancer: Future Horizons
SESSION ONE
11.05 - 12.30
Session objectives:
Chairs Prof Geraint Williams University of Cardiff, UK
Prof David Cunningham Royal Marsden Hospital, London, UK
11.05 Session introduction
Prof Gina Brown Royal Marsden Hospital and Imperial College, London, UK
11.10
Prof Iris Nagtegaal Radboud University Medical Care Academy, Nijmegen, NL
11.20
Prof Najib Haboubi Salford University, Manchester, UK
11.30
Prof Cathy Eng MD Anderson Cancer Center, Texas, US
11.40
Prof Eric Van Cutsem University of Leuven, BE
11.50
Prof Andres Cervantes University of Valencia, ES
12.00
Dr Per Nilsson Karolinska Insitute, Stockholm, SE
Dr Mariana Berho Cleveland Clinic, Florida, US
Dr Carlos Fernandez Martinez University of Valencia, ES
Dr Sheela Rao Royal Marsden Hospital, London, UK
Prof Malcolm Mason University of Cardiff, UK
Mr Alex Mirnezami University of Southampton, UK
12.30 - 13.00
Prof Angelita Habr-Gama University of Sao Paolo, BR
13.00 - 14.00 LUNCH CAVENDISH ROOM AND MAX RAYNE FOYER
What are the mechanisms behind metastatic disease?
Overcoming shortcomings of the TNM system and proposals for improvement
Long term strategies in preoperatvie chemotherapy
EXPERT ROUND TABLE DISCUSSION OF SESSION OBJECTIVES
Synchronous metastatic disease - liver first or primary first? The oncologist decides.
Are we ready for primary chemotherapy in rectal cancer? Who when and why?
SESSION TWO: ARE WE TREATING THE CORRECT PATIENTS?
What causes liver mets - lymph nodes or is it something else?
Extra nodal deposits and EMVI should they be treated the same?
Putting down the scalpel: the evolution of rectal cancer treatment
Mutational discordance: the big challenge in personalised treatments - any solutions?
Colorectal Cancer: Future Horizons
SESSION TWO
14.00 - 15.15
Session objectives:
Chairs Prof Harm Rutten Catharina Hospital, Eindhoven, NL
Prof John Nicholls St Marks Hospital and Imperial College London, UK
14.00 Session introduction
Prof Gina Brown Royal Marsden Hospital and Imperial College, London, UK
14.05
Prof Torbjorn Holm Karolinska Insitute, Stockholm, SE
14:15
Prof George Chang MD Anderson Cancer Center, Texas, US
14:25
Prof Lennart Blomqvist Karolinska Insitute, Stockholm, SE
14:35
Prof Paris Tekkis Royal Marsden Hospital and Imperial College, London, UK
14.45
Prof Té Vuong JGH, Montreal, CA
14.55
Prof Neil Mortensen University of Oxford, UK
Dr Ian Chau Royal Marsden Hospital, London, UK
Prof Robert Steele University of Dundee, UK
Dr Maria Hawkins University of Oxford, UK
Dr John Marks Lankenau Hospital, Pennsylvania, US
15.25 - 15.55 AFTERNOON TEA CAVENDISH ROOM AND MAX RAYNE FOYER
Generating evidence base for risks and impact on Quality Of Life versus benefit
use of radiotherapy to change resectability status - evidence base
Response assessment - methods of organ preservation - which is appropriate and when?
Boosting primary and recurrent rectal cancer - how far can we push the radiotherapy envelope?
EXPERT ROUND TABLE DISCUSSION OF SESSION OBJECTIVES
Should radiologists evaluate imaging response to treatment?
Many ways to organ preserve the rectum but which is correct?
Intraoperative radiotherapy - creating new surgical boundaries?
Beyond the boundaries of TME - where surgeons fear to tread
SESSION THREE: BEYOND TME AND RADIOTHERAPY
Defining resectablity in exenterative surgery - how do we reach consensus?
Colorectal Cancer: Future Horizons
SESSION THREE
15.55 - 17.15
Session objectives:
Chairs Dr Diana Tait Royal Marsden Hospital, London, UK
Mr Brendan Moran Pelican Cancer Foundation, Basingstoke, UK
15.55 Session introduction
Prof Gina Brown Royal Marsden Hospital and Imperial College, London, UK
16.00
Prof Corrie Marijnen Leiden University, NL
16.10
Prof Bengt Glimelius University of Uppsala, SE
16.20
Dr Rodrigo Perez University of Sao Paolo, BR
16.30
Dr Nancy Baxter University of Toronto, CA
Mr Chris Cunningham University of Oxford, UK
Dr Rob Glynne-Jones Mount Vernon Hospital, London, UK
Dr Miguel Rodriguez-Bigas MD Anderson Cancer Center, Texas, US
Dr Richard Adams Velindre, Cardiff, UK
Prof Vincenzo Valentini La Sapienza University of Rome, IT
17.00 - 17.15 Closing remarks
Prof Gina Brown Royal Marsden Hospital and Imperial College, London, UK
Evidence for further lines of treatment in apparent resistant tumours?
Using time and further therapy to augment response - is there evidence base?
Trying to augment response with chemotherapy - a triumph of hope over experience?
EXPERT ROUND TABLE DISCUSSION OF SESSION OBJECTIVES
SESSION FOUR: MANAGEMENT OF POOR RESPONDERS
Shaping radiotherapy treatment - should this be personalised?
What should we do for poor responders after chemoradiotherapy - bad biology or should the
fight go on?
Can patients be retreated with radiotherapy?
Colorectal Cancer: Future Horizons
SESSION FOUR